<SEC-DOCUMENT>0001193125-16-617278.txt : 20160609
<SEC-HEADER>0001193125-16-617278.hdr.sgml : 20160609
<ACCEPTANCE-DATETIME>20160609070653
ACCESSION NUMBER:		0001193125-16-617278
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160606
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160609
DATE AS OF CHANGE:		20160609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		161704893

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d206287d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): June 6, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36740</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>77-0357827</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>409 Illinois Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94158 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(415) 978-1200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report.) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June 6, 2016, our collaboration partner in Japan and Europe, Astellas
Pharma Inc. (&#147;Astellas&#148;), notified us that they had initiated their Japan Phase 3 study of roxadustat for the treatment of anemia associated with chronic kidney disease in patients on dialysis. Pursuant to our collaboration agreement with
Astellas, effective June&nbsp;1, 2005, the initiation of the first Phase 3 trial in Japan triggered a $10.0 million milestone payment that we expect to receive by July, 2016. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;FibroGen Announces Initiation by Astellas of Phase 3 Clinical Study in Japan of Roxadustat/ASP1517 for the Treatment of Anemia of Chronic Kidney Disease, Triggering $10.0 Million Milestone Payment&#148;
dated June 9, 2016</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>F<SMALL>IBROGEN</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: June 9, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Lowenstein</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michael Lowenstein</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Legal Counsel</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;FibroGen Announces Initiation by Astellas of Phase 3 Clinical Study in Japan of Roxadustat/ASP1517 for the Treatment of Anemia of Chronic Kidney Disease, Triggering $10.0 Million Milestone Payment&#148;
dated June 9, 2016</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d206287dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g206287image0012.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><B>Press Release </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen Announces Initiation by Astellas of Phase 3 Clinical Study in Japan of Roxadustat/ASP1517 for the Treatment of Anemia of Chronic Kidney Disease
Triggering $10.0 Million Milestone Payment </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco &#150; June&nbsp;9, 2016 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc. (FibroGen), announced today that it will receive a $10.0 million milestone payment from Astellas Pharma Inc. (Astellas). This payment, which
FibroGen expects to receive by July 2016, was triggered by the initiation by Astellas of the first Phase 3 clinical study in Japan of roxadustat (ASP1517 or FG-4592) for treatment of anemia associated with chronic kidney disease (CKD) in patients on
dialysis. Roxadustat, an orally administered small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHI), is the most clinically advanced candidate in this new class of potential anemia therapeutic agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the exclusive license and collaboration agreement with Astellas, Astellas is responsible for the development costs of roxadustat in Japan, and makes
payments to FibroGen for certain development, regulatory, and commercial-based milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased with the progress that our collaboration
partner Astellas has made in moving roxadustat, our first in class HIF-PHI, into Phase 3 in Japan.&#148; said Thomas B. Neff, President and Chief Executive Officer of FibroGen. &#147;Based on Phase 2 data generated in multiple settings, roxadustat
has the potential to provide a safer, more effective and more convenient alternative to erythropoiesis stimulating agents for Japanese CKD patients.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Roxadustat </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Roxadustat is currently in
Phase 3 development as a potential therapy for anemia associated with chronic kidney disease in both patients on dialysis and not on dialysis. Roxadustat is an orally administered small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl
hydroxylase activity. HIF is a protein transcription factor that induces the natural physiological response to conditions of low oxygen, &#147;turning on&#148; erythropoiesis (the process by which red blood cells are produced) and other protective
pathways.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AstraZeneca and FibroGen are collaborating on the development and commercialization of roxadustat (FG-4592) for the treatment of anemia
in patients with CKD in the U.S., China, and other markets. Astellas and FibroGen are collaborating on the development and commercialization of roxadustat in Europe, Japan, the Commonwealth of Independent States, the Middle East, and Africa.</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For information about roxadustat studies that are currently recruiting patients, please visit clinicaltrials.gov
at this link: <U>https://clinicaltrials.gov/ct2/results?term=roxadustat&amp;Search=Search</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Chronic Kidney Disease (CKD) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chronic kidney disease (CKD) affects more than 200&nbsp;million people worldwide and more than 30&nbsp;million adults in the U.S. Although the disease can
occur at any age, it becomes more common in aging populations and its prevalence is increasing. Anemia is a common complication of CKD and is associated with significant morbidity and mortality in both the dialysis and non-dialysis populations. In
addition, CKD can be both a cause and a consequence of cardiovascular disease and is now a critical worldwide healthcare issue that represents a large and growing unmet medical need. Currently, no curative treatment or ability to stop kidney
deterioration in patients with CKD exists, with the exception of kidney transplantation. <B> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About FibroGen </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious
unmet medical needs. The company utilizes its extensive experience in fibrosis and hypoxia-inducible factor (HIF) biology to generate development programs in multiple therapeutic areas. Its most advanced product candidate, roxadustat, or FG-4592, is
an oral small molecule inhibitor of HIF prolyl hydroxylases (HIF-PHs) in Phase 3 clinical development for the treatment of anemia in CKD. A second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment
of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). For more information please visit: www.fibrogen.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact Information </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>FibroGen: Leanne Price,
(415)&nbsp;978-1200, lprice@fibrogen.com <B> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains forward-looking statements, including statements regarding the clinical and commercial potential of roxadustat, the potential ability of
roxadustat to be a safer, more effective and more convenient alternative to current standard of care, future financial results, and the roxadustat Phase 3 program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our actual results may differ materially from these early data and any forward-looking statements due to risks and uncertainties that are described in our
Annual Report on Form 10-K and our quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g206287image0012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g206287image0012.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M+EYZ=NK;OV5M;KP,_P ]CD-"A5>&>)=>;@HJI[.UH\S=^2=^B2MWUTL_AO\
MX>WVO_1!+C_PYL?_ ,P-?7_\0TE_T.5_X2O_ .:#Y;_B(4?^A2__  I7_P H
M'Q_\%;+:22.)?@)."[JBY^)L8 +,%&<> #QD^E)^&LHI_P#"RO=_ZA'T_P"Y
MD:\08W2_LEK_ +F?_O<_8VORX_1PH * "@ H * "@ H * #I[ ?AC% ;>5C\
MN?CQ_P %-?!'@35-2\+?"/0(?B-J^GRO:3^*;R_:T\%17<31>9_9OV-6NO$M
MNI\^(S0RV$#/&)()[B$J\GZ'DW &+QE.GB,SK/ 4I*ZHQC>ORZVYN:T:3V=F
MIR2=I1C*Z7PN:\;X7!SG0RZBL94@[.JY6HIJWP\OO5%NKIPC=7C*2U?S[X=_
MX*P^/X=5MV\6?"SP??Z)EA=0>'=1UK2-5 *,$DM[K4KC4K<E)"C&-[<;PI4/
M&6#K[5?PWP7LY+"YC7IUE\+JQISAZ.,%3EMU4M-[/8\>CQ_BXU(_6,!1E2ZJ
MG*<)?)R<UIV:UVNMS]8/@=\?/AS^T%X5D\4_#W4Y9UL9TL]<T/4HH[37_#][
M(K/!!JM@DTJI'/$CO!<PR36\XBE6.4R6\R0_F^;Y-CLDQ*PV-IJ/,N:G4B[T
MZD5HW"5EK%Z2BTI1NKJTHM_?Y7FV"S?#NO@ZC?(^6=.2M4IOHI1N]&E>,DW%
MV=G=22]HKRCTPH * "@ H * /R:_X*Q_\D]^$O\ V.>M_P#ID2OTGPV_W[,O
M^O%/_P!.'Y_X@?[GE_\ U^G_ .D%G]C/_ADC_AG#X>_\+0_X9S_X3C?XN_MG
M_A/?^%9_\)7C_A./$G]F_P!J?\)#_I^/[)^P^1Y__+OY'E_N]E3Q3_K+_;N.
M_L_^T_J?[GV?U?ZU['_=Z7-R>R]SX^;FM]J]];E<-?ZO?V+@_KW]G?6OWW/[
M?ZM[7^/4Y>;VGO\ P<O+?[-K:6/K?0O#_P"Q/XHU6TT'PQHG[+7B+7+\S"QT
M;0M-^$VKZK>&VMYKNX%IIVGPRW%P8K2WGF?RXVV1P2.V%0D?-5JW%F&IRK8B
MKFU"C"W-.I+&0A&[45>4FHJ[:2N]6TMV?04J/#%>I&E0I976JRORPIQPDYNR
M;=HQ3;LDV[+1)O9'R-^VI^T%\8OAA^TG\)?!/@3QM>>'O"WB'P[X-O-9TB#3
MM$NHKZYU'Q[XBTB^E>?4=,N)XC+IUG;0D12H (@5 8EC]-PGDF5YAD.98O&8
M2-?$4*M>-.;E43BH8>E.*M&<8NTI-ZI[]CY[B;-\QP.=9?A<)BG0H5J=%S@H
MP:;E7J0D[RBVKQ26C6W<[#_@HK\??BW\"[?X1/\ "OQ<WA5O$TWCI-<*Z)X<
MUG[<NC)X0.F@CQ!H]^+?R3JE]_J/*W>?\^[8FWEX&R7+,WEF:S'#?6%AUA_9
M_O*M/EY_;<W\*<+WY([WM;2UW?IXRS;,,J67?4,1]7]NZ_/[E.=^3V/+_$A.
MUN:6UKWUO9'E5KIO_!5;4-"L-?TKQUX>U2VU/3K/5+&UM[?X/6]Y-:WUK'=V
M_P NH^$[:&*0Q2)E9)UP6P3P2/1E/PYIUIT*F#JTI4Y2A)MXUQ3B^5_#6DVK
MKHC@C#CV5*%6GBZ<XRC&44EA$[-77Q4HI:=V>I_L,_M8_$GXM^+?&?P=^,5K
M'/XW\(Z9J&M1ZY#IEEI%P8M&UNQT#6]&URPT]8K5-0MK_5;(0O;6T(*PW(F+
M.$)\[B_AO 99AL)F>5R<<'B9QI^S<I35YTY5*<Z<I7ERRC"5U*3U<;65SOX6
MX@QN88C$Y;F4>;%8>,IJ:C&#M"<:<X3C&T>:,I1LXQ6TKZV/F&Y_:$_;5^(O
M[2?Q0^#GPD^)5E:MH7CGXCV6@:7J/AWX>V]I9^'_  IXCU&R@MCJ6I>$[B::
M2&QA@0-/+))(5)9RQ)/T$<DX3P.0Y=FF9X"4E6P^%E4G&KB7*52K2C)ODC6B
ME>3;LDDNB/"><<38W.L=EN7XV,?8U\1&G&5/#I1ITJDHI<TJ4F[126K;?<O?
M%'XI_P#!2/\ 9WLM+\:?$CQ+I&J^$O[6M+">6#1?AKJ>CS74H:XBTW51H>@V
M6J6,-U';SQ"XC:W&052=)7BW1EV7<"9W*IA,!AYTL2H2DDZF*A-):.4/:5)T
MY.+:?*^;NXM)EX['\:9-&GB<;7A/#\ZBVH8:4+[J,N2G&I%22:NK=E)-H_3#
MP9^TGX4U[]FRR_:/UVVGT+0(_#&HZSK.FJT4]Q#JFBZA=Z%?:1IKM*JW4EUX
M@L9+2Q\QXC*;JV$OE,[*GP.*R'$T,^ED5&2K5O:QA3EJDX3C&I&<M/=4:<E*
MI9.UI6NDK_;8;.L/5R6.<U8NE15*4YQW:E"3IRA'OS5(\L+VO>-[.]OS)\,>
M/OVX/VV]<\2:K\,O%?\ PJ3X<:/J,EO;3V&M7WA;2-.GVQS6FAMXCT/3I==\
M3:V+-H9[IXT^S1F8,\5G'=6T$GZ!B,%PCPE1H4L?AO[2Q]6*;4J<:LY+5.I[
M*I)4:5/FNH)OG=K)S<927Q%#%\4<35:U3 XC^SL%2E9.,Y4H1>C4/:0BZM2=
MK.32Y5?504HQ:ZW\6?VS_P!B3Q;X7M_B_P")Q\5OAWK-UM,]]J5SXCL=5C65
M)=5M+#Q7JVFP:]I>NVUM-*T$5V3!Q&_V>X@B*!4<MX5XLPV(>68?^S<=16T8
M*E*#M:#E1A)T94Y-)2<?>W7-&3N%7,.)>&,10CF-?Z_@ZCWE)U(RUO)1JSBJ
ML9Q3?*I>[L^6458^O?VXOCS#I7[)=IXG\ ZBS6_QI;P]X?T35(@(KF+PWXFT
MB]\0:K*T$BL8I+C0M.N=,FB<!X3JKCY98QCYGA')G/B66&QM.SRGVE2<'M[6
ME.-."NMU&I)5(M:/D6Z9]%Q1FRI\/QKX2>F9^SIPDM&J=2#J2T>UX1=.2W7,
M^J/G/_@F9^SOX1UOPWK/QO\ &&C6.N:E'XBG\/\ @JSU2TCNK/3(](M[*YO]
M?2"XWQ37[W]TMO;R&,-;-IDTBDR21M;^[Q]GF)HUZ6486K*C3]DJE=P;4I<[
MDHT[JS45&-Y*_O*23T34O%X(R;#U*-3,\32C5FJCIT8R2<8<BBY5+.Z<G)VB
M[>[RMK5IK]4_B1\+? WQ8\+:CX0\;Z!8:OI=_;S11R2VUN;_ $NXEB>*/4M'
MO'B9]/U&$.2DT>,C<CAXG='_ #G 9AC,LQ%/$X2M*E4IM-I-\LTG?EG%-*47
M;5/U5FDU][C<!A<?AYX;%48U*<DTKI<T':RE!VO&2Z->CNFT_AS]DW]BOXC_
M +-7Q)NO%4WQ)T#7?"^L:'J&B:YX>LK+5;:6X#O#>:7?1FXS ]Y:WUI"OF%8
MV\FYN55@'*/]?Q)Q7@,^P$<,L!4H8BC4C.G4E*#2M>,XNVJC*+>FOO*-]KKY
M?A_AG&Y)C95WC:=6A4A*$Z<8S3>SC+72\9):Z:.5M[/Q+XY_'G]K.^_;&\3_
M +/_ ,$?'UKH\+R:+%X9T:]T'P,UG#M^&FE>,M8:?5]=\-7ES\Q&J3#S9GY*
MQ( -H'K9/DW#4.%\/G6;8)U6N=U9QJ8CF_WJ="%H4ZL8Z>XM$NK9Y>:9MQ!+
MB.OE&5XM4U[BI0E3H67^S1K3O.=.4OYGJWV1U/\ PB/_  5:_P"BD^#^/^G?
MX6__ #"US_6?#C_H K:>>+_^:#H^K\??]!M'[L+_ /*#W/\ ::^)7QN^#'[(
MWA[Q6WB>'2_C%9-X%TOQ7K]EIGAS4;>XU>[7R?$+065SH\FE^5/<HY!@LHE4
M']TL8X'C\/X#*,TXFKX98=SRN7UB=&G*=6#4(ZT[R4U4O%=YMOK<]3.\;FF6
M</4<1[=4\QC["-6I&-.2<WI4M%P=.S?:*2Z6.1_8"_:T\0_'*P\2^!?B?J\.
MJ?$7P\3KFF:HNGV.EG7O"\S06UPCVNDV%M91WVFZA)&&\M(VFAU&(K&?LLTA
MZ>,^&J&3SP^,R^DZ>!K?NY0YI3]E55VM9RE/EG%:7NHRB]?>BCGX1X@K9I"M
MA,=44\90]^,N6,.>EHGI",8J4);VM>,EI[LF<Y^T5^T-\8O O[:?P7^%'A7Q
MB^E> /%6H_"2#7_#XT/PU=K?Q>)?'MUHVMH=2U#1I]0MOM.FQI#FWNXC'MWQ
M%'):NC(\CRO%\*9KF6(POM,;AHXQTZGM*L>5TL.IT_<C.,'RR=_>B[[.ZT,<
MYSC,<)Q-EF7X?$^SP=>6$52GR4GS*I7<)^]*#FN:*MI)6W5GJ?J-7YX?='Y-
M?\%8_P#DGOPE_P"QSUO_ -,B5^D^&W^_9E_UXI_^G#\_\0/]SR__ *_3_P#2
M#YJ_9X_X)W6_QV^$'A/XIO\ %R;PLWB9M?4Z&G@5-96R_L3Q+K'AX$:B?%UB
M;CSAI0G_ ./:/9Y^SYMF]O>SOCB639GB<N66+$+#^S_>?6.2_/2A4^'V,[<O
M/R_$[VOI>QXF3\'+-<NP^/\ [0=#V_M/W?L.?E]G4G3^+VT;WY+_  JU[:VN
M?9GP!_X)U6_P+^+?A'XIQ_%V;Q,WA5M;8:&W@5-&6^_MGPYK'AX@ZBOB^]-M
MY(U8S_\ 'M+N\C9\N_>ORV<\<2S?+,3EW]F+#K$>S_>?6.?E]G5A4^'V,+WY
M.7XE:]];6/I<HX-659AA\>LQ=?ZOS^Y[#DOSTYT_B]M*UN>_PO:VE[GS5_P4
M1_Y.]^!G_8J?#_\ ]6=XKKWN!_\ DF<W_P"OV)_]1*)XG&/_ "465?\ 7K#_
M /J35.S_ ."M_P#QZ_ 3_KX^)O\ Z+\ UR^&GQ9SZ87\\0=/B%\.4^N)_*@9
M.DWG_!56;P?H\'A[2+2UT#_A'],71KNQF^!7V_\ L5=/@^P&$7FJ2W F:P$6
M"T0N 3QMEZ:5(>',<55=:JY5E4ESQDLPY?:<SYK\L%&RE?KR_(SIRX]^K4U1
MIJ-'V<>1Q>!YN3E7+:\F[\MNG-Z,R?\ @FEKWA;1_C/\3O#7CK3O$-I\=]<A
MUN!=4UR[58)+;2]3@OO&'AJXTN5([JW\7'6+5[^XEG-UYD.E3(HLWM9?[3UX
M]HXBIE67U\'.E+)J#IODIQU3G!QH55-7BZ/(^2*7+:4T_?4E[//@FK0I9ECJ
M&*A4CFM537--Z6A)2K4W%VDJO.N>3?-=0:]QQ?/\ZZ-\0?B3\,OVU?C/XH^%
M/@2X^(OBZ'XC_&:R@\,VNBZ]K\LMC=^+M72]O!IWALB]98$56+J=B[LOQ7N5
M<%@,?PGE6&S+&+ 85X7 R=5U*=-*4:,.6/-5]Q<W;=]#QZ6,QN!XFS*O@,(\
M9B(XC&15)0J5'RNM/F?+3][W>^RZFW^U9^TY^TG\2_"ND> ?B[\+#\(_#5]J
MMKK")=^"O&7AZ_URYTL3QH!=>*[A_M%A;&Z24Q64"2>9$A>5E(C&/#G#^0Y?
MB:F,RS,?[2KP@X>[7H5(TU.W2BE:4N6UYMJS=DGJ:Y_GF=8W#T\)F. _LZA*
M:G9T:U.4W"ZWJMWC&][12=UJVM#[2_:-\)Z'\.?^"<.@^%?AUK;>)O"!M_ 5
MX?$ODRV/]NZ?XC\3P>*KG6DL99%EL8+[Q!?P2I93>;);QW"P2;GA:0?*9%B:
MV-XZK8C'4?J^*3Q$?974O9RI4G15/F2M)PIQ:<U92:<E9.Q]+G.'I8+@REA\
M%5]OAK4'[2SCSQJ555<^5ZQ4JDDU%W<4^5ZJY]#_ /!/:UL+;]DSX926,<*2
MW<_C.YU)HMI:6_'CCQ%;&2X(Y,PL[:SC^;D)%&O 4 >)QM*;XES!3;M!4%"_
M2/U>D[+RYG)^K9['!\81X?P/(DG)UG*W\WMZBU\[)+T2.4_X*5VFCW'[+VL3
M:EY8O;#QAX0N?#V]MKG5GOY+*=81@[G_ +!N]:)7CY5<_P .#T\!2JQXAI1I
MWY)4:RJ?X%%25_\ N)&G\[&'&L:;R*HYV4H5J+I_X^;E=O\ N&Y_(_/WXJV>
MIW__  32_9RU)U>6'2?B7K\5PY\V1H;.;6OBE9:>Y8!PENOEPPY=U56DBC7D
MJH^TRV5.GQ[GM->ZZF%IM+1>\J>$E+MKJWHNC?F?(8^,Y<$Y-/=4\343WT3G
MBHQ^6B7EHO(^^O\ @FAXGL-:_9FT_1+9T6]\&^+O%&CZC#YJ-*#J-\/$EI<F
M)6+1PR0:UY2E@-S6<V,[3CXSC[#SH9_.JU[F*HT9P=M/<C[)J^S:=.[MLI(^
MMX(KPJY'"E'26%JU8277WI>T3MT34[+S3,O]JS]FS]IWXL_$RT\3_![XMVG@
M?PI!X4TK2)M&G^('CWPP[ZQ:7^KW%W??V=X9T2[M&62WO+)/.:42MY!5E"QJ
M3IPYGW#^69?+#9GECQ>)=:<U-8;#U;0<8*,>:K4C)6<9.UK*^CU9&?Y+GF/Q
MT:^6Y@L)AXTHP<'B*]+WU*;<N6E"4=4XJ][Z:[(^$/V*O'OQ1G_;!\)>"?$_
MQ3\6>,M+T^\^(NEWL<OC;Q)K_AC6)-%\(>*HXK^TBU2Z"7U@US:1W-M++;(V
M!%)L1QA?L>*\'E\>&,3BL/EU'"5)1PTXM4*5.K!3K4;QDX*\9)/EDE)K=7:/
ME.&<7CGQ'A\+7Q]7$TX/$0:=:I4I3Y*-5*24G:4;I2BW%='9,M?'G_A;(_X*
M.>+/^%&>5_PM,3:+_P (KY_]@>5N'P0TC^V=W_"4?\2S_D7O[6Q]J[X\O]]Y
M=3DW]FK@7#?VO?\ LZU3VUO:7_W^?)_!_>?Q.3X?G[MRLV_M!<9XC^RK?7[P
M]E?V=O\ <H<_\7]W_#Y_B^6MCWO_ (VV_P#4*_\ -?Z\;_C6O]__ ,R)ZO\
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> % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
